Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling

BACKGROUND AND PURPOSE: CX‐5461 is a novel selective RNA polymerase I (Pol I) inhibitor. Previously, we found that CX‐5461 could inhibit pathological arterial remodelling caused by angioplasty and transplantation. In the present study, we explored the pharmacological effects of CX‐5461 on experiment...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xia, Feng, Hua, Dai, Chaochao, Lu, Weida, Zhang, Jun, Guo, Xiaosun, Yin, Qihui, Wang, Jianli, Cui, Xiaopei, Jiang, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328314/
https://www.ncbi.nlm.nih.gov/pubmed/33486761
http://dx.doi.org/10.1111/bph.15385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328314/
https://www.ncbi.nlm.nih.gov/pubmed/33486761
http://dx.doi.org/10.1111/bph.15385

Ejemplares similares